Rich Pharmaceuticals (RCHA) 10-Q 23 Nov 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2015	Oct. 09, 2015
Document And Entity Information
Entity Registrant Name	Rich Pharmaceuticals, Inc.
Entity Central Index Key	1,504,389
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		4,420,461,736
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,015

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2015	Mar. 31, 2015
Current Assets
Cash and equivalents		$ 15,892
Prepaid expenses	$ 2,093	7,578
Total Current Assets	2,093	23,470
Property and equipment, net	552	788
TOTAL ASSETS	2,645	24,258
Current Liabilities
Accounts payable	910,803	$ 910,272
Bank overdraft	484
Accrued expenses	338,289	$ 200,891
Due to related parties	37,874	6,067
Convertible notes payable, net of debt discount	183,362	402,131
Derivative liabilities	405,496	139,983
Total Current Liabilities	1,876,308	1,659,344
Long-term Liabilities
Convertible notes payable, net of debt discount	2,307	6,080
Derivative liabilities	33,370	77,775
Total Long-term Liabilities	35,677	83,855
Total Liabilities	1,911,985	1,743,199
Stockholders Deficit
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively	6,000	6,000
Common stock, $.001 par value, 37,503,000,000 shares authorized, 4,072,077,779 and 1,541,083,957 shares issued and outstanding,	4,072,077	1,541,083
Additional paid-in capital	2,404,530	4,168,956
Accumulated deficit	(8,391,947)	(7,434,980)
Total Stockholders Deficit	(1,909,340)	(1,718,941)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$ 2,645	$ 24,258

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Mar. 31, 2015	Sep. 06, 2013	Sep. 05, 2013
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized	37,503,000,000	37,503,000,000	37,503,000,000	90,000,000
Common Stock, Issued	4,072,077,779	1,541,083,957
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Issued	6,000,000	6,000,000

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Consulting expenses		$ 81,211	$ 6,000	$ 161,211
Office expenses	$ 25,140	19,480	45,894	42,317
Depreciation expense	118	118	236	236
Wages and taxes	91,071	94,877	182,793	245,955
Professional fees	26,338	203,664	92,285	329,543
Regulatory fees	15,580	$ 34,582	17,249	$ 35,647
Research and development	2,000		9,000
Stock-based compensation	62,301	$ 61,149	192,392	$ 181,441
Travel, meals and entertainment	11,980	22,746	14,592	39,685
TOTAL OPERATING EXPENSES	234,528	517,827	560,442	1,036,035
LOSS FROM OPERATIONS	(234,528)	(517,827)	(560,442)	(1,036,035)
OTHER INCOME (EXPENSE)
Amortization of debt discount	(101,837)	(26,785)	(270,988)	(28,423)
Change in value of derivative liability	180,446	(8,735)	230,186	(8,735)
Derivative expense	(142,073)	(109,872)	335,244	109,872
Interest expense	(11,082)	$ (7,680)	(20,255)	$ (9,929)
Interest expense related party	(150)		(224)
Other Income Total	(74,696)	$ (153,072)	(396,525)	$ (155,321)
LOSS BEFORE PROVISION FOR INCOME TAXES	$ (309,224)	$ (670,899)	$ (956,967)	$ (1,191,356)
PROVISION FOR INCOME TAXES
NET LOSS	$ (309,224)	$ (670,899)	$ (956,967)	$ (1,191,356)
NET LOSS PER SHARE: BASIC AND DILUTED	$ 0	$ 0	$ 0	$ 0
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	3,556,918,656	421,636,100	5,682,706,764	419,376,122

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (309,224)	$ (670,899)	$ (956,967)	$ (1,191,356)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	118	118	236	236	$ 473
Amortization of debt discount	101,837	26,785	270,988	28,423
Change in value of derivative liability	(180,446)	8,735	(230,186)	8,735
Derivative expense	(142,073)	(109,872)	335,244	$ 109,872
Warrants issued for services			13,259
Stock-based compensation	$ 62,301	61,149	192,392	$ 181,441
Changes in operating assets and liabilities:
Decrease in prepaid expenses			5,485
Increase (Decrease) in accounts payable			531	$ (10,583)
Increase in accrued expenses			137,398	$ 123,185
Increase in bank overdraft			484
Net Cash Used by Operating Activities			$ (231,136)	$ (750,047)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of intangible assets
Net Cash Used by Investing Activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans received (repaid) from/to related parties			$ 30,417	$ (36,000)
Proceeds from sale of common stock and warrants			50,873	340,000
Issuance of convertible note payable			133,954	437,500
Net Cash Provided by Financing Activities			215,244	741,500
Net Increase (Decrease) in Cash and Cash Equivalents			(15,892)	(8,547)
Cash and cash equivalents, beginning of period			$ 15,892	12,387	12,387
Cash and cash equivalents, end of period		$ 3,840		$ 3,840	$ 15,892	$ 12,387
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Stock deposits reclassified as common stock and stock warrants				$ 147,050		$ 147,050
Common stock issued for accrued expense				330,000
Original issue discounts recorded on notes payable			$ 5,400	20,975
Debt discounts recorded on convertible notes payable			330,902	206,500
Debt/interest converted into common stock			$ 308,451	$ 12,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 531,292,500 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 500,255,434 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.001, from 90,000,000 shares to 37,503,000,000 shares. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2015 and March 31, 2015 the Company had $-- and $15,892, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015, as filed with the U.S. Securities and Exchange Commission. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company acquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at September 30, 2015 and 2014. As of September 30, 2015, the derivative liabilities were considered a level 2 item; see Note 8. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 390,004,800 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 19,750,000 stock options to officers, directors, employees and consultants. During the period ended September 30, 2015, the Company granted 304,000,250 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.0017; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.0008 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.0001 per share. Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and Equipment

Property and Equipment	6 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property and equipment	Property and equipment, recorded at cost, consisted of the following as of September 30, 2015 and March 31, 2015: September 30, 2015 March 31, 2015 Computer equipment $ 1,419 $ 1,419 Less: accumulated depreciation (867 ) (631 ) Property and equipment, net $ 552 $ 788 The useful life of the computer equipment is 3 years. Depreciation expense was $236 and $473 for the periods ended September 30, 2015 and March 31, 2015, respectively .

Intangible Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consisted of the following as of September 30, 2015 and March 31, 2015: September 30, 2015 March 31, 2015 Wages and taxes 313,822 175,357 Accrued interest 24,467 25,534 Consulting 0 0 Total accrued expenses $ 338,289 $ 200,891

Related Party Debt and Transact

Related Party Debt and Transactions	6 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Debt and Transactions	On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with its boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. During the year ended March 31, 2015 and 2014, the Company received loans from companies controlled by its new CEO or shareholders totaling $5,000 and $36,000, respectively. The loans are unsecured, non-interest bearing with no specific terms of repayment. The Company repaid all $41,000 of the loans during the year ended March 31, 2015. Also during the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. The loan is unsecured and bears 8% interest. The total due was $6,000 as of September 30, 2015. Interest accrued on the 2015 note as of September 30, 2015 was $217. During the period ending September 30, 2015, the Company received $24,200 in unsecured non-interest bearing loans from related parties. These loans are deemed to be short-term and are payable at the discretion of the Company. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 3,000,240 shares of common stock at an exercise price of $0.02 per share. The CEO earned $137,500 and $151,422 for the six months ended September 30, 2015 and 2014 (respectively) as a result of this agreement, of which $258,130 and $154,062 is included in accrued expenses, as of September 30, 2015 and March 31, 2015.

Stock Deposits

Stock Deposits	6 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Stock Deposits	The Company received deposits for future stock purchases during the year ended March 31, 2014 totaling $147,050. The Company signed subscription agreements with four investors on June 16, 2014 to grant 1,469,000 shares of common stock in exchange for the deposits. The remaining balance as of March 31, 2015 and September 30, 2015 is $0.

Convertible Note Payable

Convertible Note Payable	6 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Convertible Note Payable	On March 11, 2014, the Company issued a convertible promissory note in the amount of $37,500. The note is due on December 13, 2014 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $37,500 of principal and $1,500 of interest into 2,159,271 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On April 8, 2014, the Company issued a convertible note payable in the amount of $53,000. The note bears 8% interest and is due on January 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date . On May 21, 2014, the Company issued a convertible note payable in the amount of $42,500. The note bears 8% interest and is due on February 23, 2015. The note is currently in default. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $42,500 of principal and $1,700 of interest into 15,252,347 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $3,380. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $66,780 of principal and $2,850 of interest into 121,442,490 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $58,300 of principal and $2,527 of interest into 131,091,236 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 140,370,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $1,067 as of September 30, 2015. On August 19, 2014, the Company issued a convertible note payable in the amount of $57,895 including an original issue discount of $2,895. The note bears 12% interest and is due on August 19, 2016. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $57,895 of principal and $14,035 of interest (including a $10,000 penalty) into 179,825,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 18,181,818 shares of common stock leaving a remaining balance of $54,500. During the period ending September 30, 2015 the note holder converted $54,500 in principal and $8,240 in accrued interest into 187,959,744 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of September 30, 2015. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 70,000,000 common shares leaving a remaining balance of $29,800. During the period ending September 30, 2015 the note holder converted $29,800 in principal and $2,158 in accrued interest into 86,467,222 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of September 30, 2015. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending September 30, 2015 the note holder converted $33,000 in principal and $1,320 in accrued interest into 78,000,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of September 30, 2015. On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date . On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending September 30, 2015 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $45,980 in principal into 281,363,421 shares of common stock leaving a remaining balance of $530. Accrued interest was $2,064 as of September 30, 2015. The Company is in default on the balance of this note. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending September 30, 2015 the note holder converted $32,472 in principal into 423,700,000 shares of common stock leaving a remaining balance of $861. Accrued interest was $5,262 as of September 30, 2015. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended September 30, 2015 is $1,909. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note as of September 30, 2015 is $2,805. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending September 30, 2015 the note holder converted $32,280 in principal and $755 in accrued interest into 331,318,989 shares of common stock leaving a remaining balance of $34,500. Accrued interest was $1,701 as of September 30, 2015. The Company is in default on the balance of this note. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on December 9, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending September 30, 2015 the note holder converted $5,708 in principal and $2,266 in accrued interest into 177,203,333 shares of common stock leaving a remaining balance of $49,292. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 121,555,062 common shares leaving a remaining balance of $1,898. During the period ending September 30, 2015 the note holder converted $1,898 in principal and $20 in accrued interest into 5,300,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of September 30, 2015. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date.

Derivative Liabilities

Derivative Liabilities	6 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Derivative Liabilities	In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the years ending March 31, 2015 and 2016: $37,500 note dated March 11, 2014; $53,000 note dated April 8, 2014; $42,500 note dated May 21, 2014; $55,000 note dated September 23, 2014; $66,780 note dated August 14, 2014; $58,300 note dated August 14, 2014; $64,500 note dated September 18, 2014; $58,300 note dated March 2, 2015; $61,111 note dated August 13, 2014; $57,895 note dated August 19, 2014; $33,333 note dated December 16, 2014; $27,778 note dated February 25, 2015; $33,000 noted dated October 6, 2014; $55,000 note dated November 6, 2014; $43,000 note dated November 25, 2014; $68,900 note dated May 5, 2015; $16,500 note dated May 27, 2015; $10,500 note dated May 6, 2015; $15,000 note dated August 28, 2015; $19,000 note dated September 4, 2015. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended September 30, 2015, the Company recorded a total change in the fair market value of the derivative liabilities of $230,186. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0001 - $0.0008, exercise price of $0.00006 - $0.000483, dividend yield of zero, years to maturity of 0.0356 – 1.46, a risk free rate of 0.01% - 0.33%, and annualized volatility of 56% - 713%.

Equity Transactions

Equity Transactions	6 Months Ended
	Sep. 30, 2015
Equity Transactions
Equity Transactions	The Company has 37,503,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series “A” Preferred Stock. The Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company granted 6,000,000 Series “A” Preferred shares and 82,767,038 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973. On July 19, 2013, our new officer/director agreed to cancel 500,255,434 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares from 90,000,000 to 37,503,000,000. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. On October 29, 2013, the Company granted 250,000 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 11, 2013, the Company granted 250,000 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On March 10, 2014, the Company issued 83,334 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 250,000 250,000 83,334 Stock price on grant date $0.30 $0.02 $0.02 Exercise price $0.50 $0.50 $0.50 Expected life 1 year 1 year 1 year Volatility 147% 64% 65% Risk-free rate 0.12% 0.11% 0.13% Calculated value $10,473 $0 $0 Fair value allocation of proceeds $7,381 $0 $0 On April 4, 2014, the Company issued 83,334 units at $0.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.50 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On April 24, 2014, the Company issued 1,000,000 units at $0.25 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.35 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 10, 2014, the Company issued 700,000 units at $0.043 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.15 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 29, 2014, the Company issued 700,000 units at $0.05 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $0.15 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On June 9, 2014, the Company issued 90,000,000 units at $0.0002 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.0002 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 June 9, 2015 Warrants 83,334 1,000,000 700,000 700,000 90,000,000 Stock price on grant date $0.199 $0.252 $0.037 $0.037 $0.0002 Exercise price $0.50 $0.35 $0.15 $0.15 $0.0002 Expected life 1 year 3 year 3 year 3 year 5 year Volatility 113% 76% 119% 119% 98% Risk-free rate 0.12% 0.84% 0.96% 0.98% 1.74% Calculated value $3,181 $104,416 $12,130 $12,102 $13,259 Fair value allocation of proceeds $2,822 $73,653 $8,637 $8,992 $13,259 The following is a summary of the warrant activity for the period from April 1, 2013 to September 30, 2015: Number of warrants Weighted average exercise price Outstanding, April 1, 2013 - $0.00 Granted 583,334 $0.50 Exercised - - Outstanding, March 31, 2014 583,334 $0.50 Granted 2,483,334 $0.24 Exercised - - Outstanding, March 31, 2015 3,066,668 $0.29 Granted 90,000,000 $0.0002 Exercised - - Outstanding, September 30, 2015 93,066,668 $0.0097 On May 7, 2014, the Company granted 2,500,000 shares to a consultant for prior services rendered. The Company had accrued $300,000 for these services as of March 31, 2014. On June 16, 2014, the Company issued 1,469,000 shares of common stock for stock deposits of $147,050. The Company had received the deposits during the year ended March 31, 2014. On July 1, 2014, the Company granted 1,000,000 shares to a professional for prior legal services rendered. The Company had accrued $30,000 for these services as of June 30, 2014. The shares were valued on the grant date at the fair market value of $60,000 resulting in a loss on the issuance of shares of $30,000. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC, a related party, and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value of $7,822,235 as a deemed dividend reducing additional paid in capital. Also on October 6, 2014, the Board of Directors approved the issuance of 8,000,000 shares of common stock to the CEO and 4,000,000 shares of common stock to the Company’s attorney as bonuses. The shares were valued based on the closing stock price on the grant date for a total value of $429,600. On November 19, 2014, the Company entered into an agreement with an unrelated vendor to provide six months of consulting services in exchange for 500,000 shares of common stock. The shares were valued based on the closing stock price on the grant date for a total value of $6,450. The entire contract was expensed as of March 31, 2015. On August 13, 2014, the Company entered into an investment agreement with an investor to invest up to $4,000,000 to purchase the Company’s common stock. The price per share for each investment is determined by the lesser of: (1) 65% of the lowest traded price of the Company’s common stock during the ten consecutive trading days prior to the drawdown notice date or (2) 65% of the closing bid price on the day before the drawdown notice is submitted. During the year ended March 31, 2015, the Company issued 79,961,892 shares of common stock to this investor for total proceeds of $220,000. On April 22, 2015, the Company sold 10,038,108 shares of common stock for $5,405 in cash, which was paid directly to a vendor for accounts payable. On June 25, 2015, the Company sold 154,245,477 shares of common stock for $10,797 in cash, of which $3,750 was paid directly to professionals in connection with the expenses of that sale, and $7,047 was retained by the Company. On July 7, 2015, the Company sold 161,942,326 shares of common stock for $11,336 in cash, of which $3,750 was paid directly to a vendor for professional services. On July 15, 2015, the Company sold 143,928,240 shares of common stock for $10,075 in cash. During the year ended March 31, 2015 and the period ended September 30, 2015, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share September 22, 2014 $12,000 550,459 $0.0218 October 1, 2014 $12,000 648,649 $0.0185 October 8, 2014 $9,000 505,618 $0.0178 October 16, 2014 $6,000 454,545 $0.0132 October 29, 2014 $15,000 1,250,000 $0.0120 November 3, 2014 $10,000 819,672 $0.0122 November 7, 2014 $12,000 1,188,119 $0.0101 November 19, 2014 $18,120 2,831,250 $0.0064 December 8, 2014 $15,000 3,488,372 $0.0043 December 15, 2014 $12,000 4,285,714 $0.0028 December 26, 2014 $17,200 7,478,261 $0.0023 February 11, 2015 $29,900 74,750,000 $0.0004 February 12, 2015 $17,333 37,356,055 $0.00046 February 13, 2015 $17,894 37,280,000 $0.00048 February 15, 2015 $35,730 73,924,324 $0.00048 February 17, 2015 $17,003 36,643,945 $0.00046 February 23, 2015 $20,603 47,090,000 $0.00044 February 23, 2015 $17,003 36,643,945 $0.00046 February 24, 2015 $9,488 20,447,291 $0.00046 February 26, 2015 $42,030 105,075,000 $0.0004 February 27, 2015 $26,880 56,000,000 $0.00048 March 2, 2015 $56,402 121,555,062 $0.00046 March 9, 2015 $33,900 47,518,166 $0.00071 March 10, 2015 $25,200 70,000,000 $0.00036 March 20, 2015 $10,000 18,181,818 $0.00006 March 31, 2015 Total $498,686 805,966,265 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 41,111,111 $0.00041 April 6, 2015 $10,000 20,964,361 $0.00048 April 8, 2015 $15,309 45,356,111 $0.00034 April 8, 2015 $20,001 45,454,545 $0.00044 April 9, 2015 $14,320 32,545,455 $0.00044 April 14, 2015 $10,000 23,696,682 $0.00042 April 16, 2015 $1,918 5,300,000 $0.00036 April 21, 2015 $10,000 25,974,026 $0.00039 April 29, 2015 $15,000 38,961,039 $0.00039 May 4, 2015 $5,083 13,146,439 $0.00039 May 12, 2015 $28,456 90,337,960 $0.00031 May 20, 2015 $20,199 94,764,514 $0.00021 May 20, 015 $17,240 78,363,636 $0.00022 May 27, 2015 $13,568 70,180,137 $0.00019 May 29, 2015 $15,000 88,235,295 $0.00017 June 11, 2015 $9,897 94,260,947 $0.00010 June 16, 2015 $14,100 117,500,000 $0.00012 June 16, 2015 $13,565 113,041,667 $0.00012 June 22, 2015 $7,415 123,583,333 $0.00006 June 22, 2015 $14,384 247,992,413 $0.00006 June 23, 2015 $7,752 129,200,000 $0.00006 September 16, 2015 $7,974 177,203,333 $0.000045 September 28, 2015 $10,000 166,666,667 $0.00006 September 29, 2015 $10,620 177,000,000 $0.00006 Sept 30, 2015 Total $308,451 2,060,840 The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined. During the year ended March 31, 2014, the Company granted 47,503,280 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 19,750,000 stock options to officers, directors, employees and consultants. During the period ended September 30, 2015, the Company granted 304,000,250 stock options to officers, directors, employees and consultants The options have been re-priced twice as follows: (1) Effective January 12, 2015, the Company approved the re-pricing of all 67,253,280 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.0191984 per share and $0.30 per share, to $0.0017 per share which was the closing price of the Company’s common stock on January 9, 2015. All of the other terms of the options remained unchanged. (2) Effective April 6, 2015, the Company approved the re-pricing of all 271,253,530 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.0008 per share and $0.0017 per share, to $0.0008 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 371,253,530 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.0008 per share and $0.0002 per share, to $0.0002 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date September 6, 2013 February 7, 2014 March 14, 2014 May 7, 2014 July 23, 2014 October 6, 2014 April 6, 2015 June 9, 2015 Options 41,003,280 1,500,000 5,000,000 3,500,000 750,000 15,500,000 204,000,250 100,000,000 Stock price grant date $0.02 $0.02 $0.30 $0.12 $0.069 $.0358 $0.0008 $0.0002 Initial Exercise price $0.0191984 $0.0191984 $0.30 $0.12 $0.069 $0.0191984 $0.0008 $0.0002 Modified Exercise price $0.0001 $0.0001 $0.0001 $0.0001 $0.0001 $0.0001 $0.0001 $0.0001 Expected life 10.00 10.00 10.00 10.00 10.00 5.0 5.0 5.0 Volatility 76% 74% 74% 73% 88% 101% 99% 99% Risk-free rate 2.94% 2.71% 2.65% 2.56% 2.53% 1.04% 1.31% 1.74% Calculated value $663,307 $23,825 $1,182,141 $315,772 $45,109 $454,798 $120,778 $14,838 Modified value $83,850 $3,069 $10,232 $7,164 $1,537 $31,408 $151,221 $16,347 The following is a summary of the option activity for the period April 1, 2013 through September 30, 2015: Number of options Weighted average exercise price Outstanding, April 1, 2013 - $0.00 Granted 47,503,280 $0.0001 Exercised - - Outstanding, March 31, 2014 47,503,280 $0.0001 Granted 19,750,000 $0.0001 Exercised - - Expired - - Outstanding, March 31, 2015 67,253,280 $0.0001 Granted 304,000,250 $0.0001 Exercised - - Expired - - Outstanding, September 30, 2015 371,253,530 $0.0001

Commitments and Contigencies

Commitments and Contigencies	6 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Commitments and Contingencies	The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,600. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. In January 2015, the trial in the Litigation was concluded in the Court. The Court has not rendered a verdict in the Litigation as of the date of filing. The Company believes the allegations in the complaint are without merit and the Company intends to defend itself in the Litigation. However, the Company has incurred expenses and the diversion of financial resources and management personnel in responding to the complaint. Additionally, an adverse determination against the Company in the Litigation may subject us to significant liabilities or require us to seek licenses that may not be available from third parties on commercially favorable terms, if at all. Further, an adverse determination against the Company in the Litigation may require us to pay substantial financial damages, which can be tripled if the infringement is deemed willful, or be required to discontinue or significantly delay development, marketing, selling and licensing of the Company’s affected products and intellectual property rights.

Liquidity and Going Concern

Liquidity and Going Concern	6 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

Income Taxes

Income Taxes	6 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	As of September 30, 2015, the Company had net operating loss carry forwards of approximately $8,391,947 that may be available to reduce future years’ taxable income in varying amounts through 2033. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The provision for Federal income tax consists of the following for the period ended September 30, 2015 and the year ended March 31, 2015: September 30, 2015 March 31, 2015 Federal income tax benefit attributable to: Current operations $ 325,369 $ 1,405,416 Less: valuation allowance (325,369 ) (1,405,416 ) Net provision for Federal income taxes $ -- $ -- The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows as of September 30, 2015 and March 31, 2015: September 30, 2015 March 31, 2015 Deferred tax asset attributable to: Net operating loss carryover $ 2,780,320 $ 2,454,951 Less: valuation allowance (2,780,320 ) (2,454,951 ) Net deferred tax asset $ -- $ -- Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of approximately $8,391,947 for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

Subsequent Events

Subsequent Events	6 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Subsequent Events	On September 29, 2015, the Company issued 177,203,333 shares of Company common stock to satisfy the conversion of $7974.15 of a convertible note payable. On September 28, 2015, the Company issued 166,666,667 shares of Company common stock to satisfy the conversion of $10,000.00 of a convertible note payable. On October 7, 2015, the Company issued 37,500,000 shares of Company common stock to satisfy the conversion of $2,250 of a convertible note payable. On October 7, 2015, the Company issued 140,000,000 shares of Company common stock to satisfy the conversion of $8,400 of a convertible note payable. On October 5, 2015, the Company received an unsecured non-interest bearing short-term loan from a related party of $4,000. In accordance with ASC 855-10, the Company has analyzed its operations subsequent to September 30, 2015 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Nature of Business	On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 531,292,500 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 500,255,434 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 262,521,000 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.001, from 90,000,000 shares to 37,503,000,000 shares. Correspondingly, the Company affirmed a forward split of 416.7 for 1 in which each shareholder was issued 416.7 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split.
Cash and Cash Equivalents	The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At September 30, 2015 and March 31, 2015 the Company had $-- and $15,892, respectively, of unrestricted cash.
Basis of Presentation	The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015, as filed with the U.S. Securities and Exchange Commission.
Property and Equipment	Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.
Long-Lived and Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 82,767,038 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 220,792,028 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at September 30, 2015 and 2014. As of September 30, 2015, the derivative liabilities were considered a level 2 item; see Note 8.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Income Taxes	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Revenue Recognition	The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.
Stock-Based Compensation	Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 390,004,800 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 19,750,000 stock options to officers, directors, employees and consultants. During the period ended September 30, 2015, the Company granted 304,000,250 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.0017; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.0008 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.0001 per share.
Basic loss per share	The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.
Recent Accounting Pronouncements	The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment (Tables)

Property and equipment (Tables)	6 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	September 30, 2015 March 31, 2015 Computer equipment $ 1,419 $ 1,419 Less: accumulated depreciation (867 ) (631 ) Property and equipment, net $ 552 $ 788

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	September 30, 2015 March 31, 2015 Wages and taxes 313,822 175,357 Accrued interest 24,467 25,534 Consulting 0 0 Total accrued expenses $ 338,289 $ 200,891

Equity Transactions (Tables)

Equity Transactions (Tables)	6 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Schedule of Value of Warrants	Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 250,000 250,000 83,334 Stock price on grant date $0.30 $0.02 $0.02 Exercise price $0.50 $0.50 $0.50 Expected life 1 year 1 year 1 year Volatility 147% 64% 65% Risk-free rate 0.12% 0.11% 0.13% Calculated value $10,473 $0 $0 Fair value allocation of proceeds $7,381 $0 $0 Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 June 9, 2015 Warrants 83,334 1,000,000 700,000 700,000 90,000,000 Stock price on grant date $0.199 $0.252 $0.037 $0.037 $0.0002 Exercise price $0.50 $0.35 $0.15 $0.15 $0.0002 Expected life 1 year 3 year 3 year 3 year 5 year Volatility 113% 76% 119% 119% 98% Risk-free rate 0.12% 0.84% 0.96% 0.98% 1.74% Calculated value $3,181 $104,416 $12,130 $12,102 $13,259 Fair value allocation of proceeds $2,822 $73,653 $8,637 $8,992 $13,259
Schedule of Warrant Activity	Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 June 9, 2015 Warrants 83,334 1,000,000 700,000 700,000 90,000,000 Stock price on grant date $0.199 $0.252 $0.037 $0.037 $0.0002 Exercise price $0.50 $0.35 $0.15 $0.15 $0.0002 Expected life 1 year 3 year 3 year 3 year 5 year Volatility 113% 76% 119% 119% 98% Risk-free rate 0.12% 0.84% 0.96% 0.98% 1.74% Calculated value $3,181 $104,416 $12,130 $12,102 $13,259 Fair value allocation of proceeds $2,822 $73,653 $8,637 $8,992 $13,259
Schedule of Conversions of Common Stock	Date Debt/Interest Converted Common Stock Issued Price per Share September 22, 2014 $12,000 550,459 $0.0218 October 1, 2014 $12,000 648,649 $0.0185 October 8, 2014 $9,000 505,618 $0.0178 October 16, 2014 $6,000 454,545 $0.0132 October 29, 2014 $15,000 1,250,000 $0.0120 November 3, 2014 $10,000 819,672 $0.0122 November 7, 2014 $12,000 1,188,119 $0.0101 November 19, 2014 $18,120 2,831,250 $0.0064 December 8, 2014 $15,000 3,488,372 $0.0043 December 15, 2014 $12,000 4,285,714 $0.0028 December 26, 2014 $17,200 7,478,261 $0.0023 February 11, 2015 $29,900 74,750,000 $0.0004 February 12, 2015 $17,333 37,356,055 $0.00046 February 13, 2015 $17,894 37,280,000 $0.00048 February 15, 2015 $35,730 73,924,324 $0.00048 February 17, 2015 $17,003 36,643,945 $0.00046 February 23, 2015 $20,603 47,090,000 $0.00044 February 23, 2015 $17,003 36,643,945 $0.00046 February 24, 2015 $9,488 20,447,291 $0.00046 February 26, 2015 $42,030 105,075,000 $0.0004 February 27, 2015 $26,880 56,000,000 $0.00048 March 2, 2015 $56,402 121,555,062 $0.00046 March 9, 2015 $33,900 47,518,166 $0.00071 March 10, 2015 $25,200 70,000,000 $0.00036 March 20, 2015 $10,000 18,181,818 $0.00006 March 31, 2015 Total $498,686 805,966,265 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 41,111,111 $0.00041 April 6, 2015 $10,000 20,964,361 $0.00048 April 8, 2015 $15,309 45,356,111 $0.00034 April 8, 2015 $20,001 45,454,545 $0.00044 April 9, 2015 $14,320 32,545,455 $0.00044 April 14, 2015 $10,000 23,696,682 $0.00042 April 16, 2015 $1,918 5,300,000 $0.00036 April 21, 2015 $10,000 25,974,026 $0.00039 April 29, 2015 $15,000 38,961,039 $0.00039 May 4, 2015 $5,083 13,146,439 $0.00039 May 12, 2015 $28,456 90,337,960 $0.00031 May 20, 2015 $20,199 94,764,514 $0.00021 May 20, 015 $17,240 78,363,636 $0.00022 May 27, 2015 $13,568 70,180,137 $0.00019 May 29, 2015 $15,000 88,235,295 $0.00017 June 11, 2015 $9,897 94,260,947 $0.00010 June 16, 2015 $14,100 117,500,000 $0.00012 June 16, 2015 $13,565 113,041,667 $0.00012 June 22, 2015 $7,415 123,583,333 $0.00006 June 22, 2015 $14,384 247,992,413 $0.00006 June 23, 2015 $7,752 129,200,000 $0.00006 September 16, 2015 $7,974 177,203,333 $0.000045 September 28, 2015 $10,000 166,666,667 $0.00006 September 29, 2015 $10,620 177,000,000 $0.00006 Sept 30, 2015 Total $308,451 2,060,840
Schedule of Value of Options	Date September 6, 2013 February 7, 2014 March 14, 2014 May 7, 2014 July 23, 2014 October 6, 2014 April 6, 2015 June 9, 2015 Options 41,003,280 1,500,000 5,000,000 3,500,000 750,000 15,500,000 204,000,250 100,000,000 Stock price grant date $0.02 $0.02 $0.30 $0.12 $0.069 $.0358 $0.0008 $0.0002 Initial Exercise price $0.0191984 $0.0191984 $0.30 $0.12 $0.069 $0.0191984 $0.0008 $0.0002 Modified Exercise price $0.0001 $0.0001 $0.0001 $0.0001 $0.0001 $0.0001 $0.0001 $0.0001 Expected life 10.00 10.00 10.00 10.00 10.00 5.0 5.0 5.0 Volatility 76% 74% 74% 73% 88% 101% 99% 99% Risk-free rate 2.94% 2.71% 2.65% 2.56% 2.53% 1.04% 1.31% 1.74% Calculated value $663,307 $23,825 $1,182,141 $315,772 $45,109 $454,798 $120,778 $14,838 Modified value $83,850 $3,069 $10,232 $7,164 $1,537 $31,408 $151,221 $16,347
Schedule of Option Activity	Number of options Weighted average exercise price Outstanding, April 1, 2013 - $0.00 Granted 47,503,280 $0.0001 Exercised - - Outstanding, March 31, 2014 47,503,280 $0.0001 Granted 19,750,000 $0.0001 Exercised - - Expired - - Outstanding, March 31, 2015 67,253,280 $0.0001 Granted 304,000,250 $0.0001 Exercised - - Expired - - Outstanding, September 30, 2015 371,253,530 $0.0001

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Schedule of Federal Income Tax	September 30, 2015 March 31, 2015 Federal income tax benefit attributable to: Current operations $ 325,369 $ 1,405,416 Less: valuation allowance (325,369 ) (1,405,416 ) Net provision for Federal income taxes $ -- $ --
Schedule of Deferred Tax Asset	September 30, 2015 March 31, 2015 Deferred tax asset attributable to: Net operating loss carryover $ 2,780,320 $ 2,454,951 Less: valuation allowance (2,780,320 ) (2,454,951 ) Net deferred tax asset $ -- $ --

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Details Narrative)	6 Months Ended	12 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Date Of Incorporation	Aug. 9, 2010
Common Stock, shares issued		1,469,000
Common Stock, Shares Authorized	37,503,000,000	37,503,000,000	37,503,000,000	90,000,000
Common Stock, Par Value | $ / shares	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Stock split ratio	416.7
Cash and cash equivalent | $		$ 15,892
Intangible assets | $		$ 0
Impairment of intangible asset | $	$ 82,120
Reserved common shares	390,004,800
Computer equipment	3 years
Options granted, number of shares	304,000,250	19,750,000
Options, exercise price | $ / shares	$ 0.0008
Sale Agmt
Date of Agreement	Jan. 19, 2013
Cancellation of loans | $	$ 28,818
Shares sold by former officers	531,292,500
Shares returned to treasury	500,255,434
Shares agreed to cancel	262,521,000
Asset Assign Agmt
Date of Agreement	Jul. 18, 2013
Common Stock, shares issued	82,767,038
Series A Preferred Stock, shares issued	6,000,000
Date of Termination	Jan. 17, 2014
Termination of agreement | $	$ 20,000

Property and equipment - Schedu

Property and equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2015	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Computer equipment	$ 1,419	$ 1,419
Less: accumulated depreciation	(867)	(631)
Property and equipment, net	$ 552	$ 788

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Property And Equipment Details Narrative
Depreciation expense	$ 118	$ 118	$ 236	$ 236	$ 473
Computer equipment			3 years

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2015	Mar. 31, 2015
Common Stock, shares issued		1,469,000
Impairment of intangible asset	$ 82,120
Asset Assign Agmt #2
Date of Agreement	Oct. 6, 2014
Common Stock, shares issued	220,792,028
Common stock, value	$ 7,904,355
Impaired Assets		$ 0
Impairment of intangible asset	$ 82,120
Consulting Agreement
Date of Agreement	Jul. 18, 2013
Common Stock, shares issued	82,767,038
Series A Preferred Stock, shares issued	6,000,000
Common stock, value	$ 123,973
Series A Preferred Stock, value	45,000
Impaired Assets	$ 0

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2015	Mar. 31, 2015
Payables and Accruals [Abstract]
Wages and taxes	$ 313,822	$ 175,357
Accrued interest	$ 24,467	$ 25,534
Consulting
Total accrued expenses	$ 338,289	$ 200,891

Related Party Debt and Transa29

Related Party Debt and Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015	Mar. 31, 2014
Due to related parties	$ 37,874		$ 37,874		$ 6,067
Loans and interest received (repaid) from/to related parties			30,417	$ (36,000)
Interest expense, related party	$ (150)		$ (224)
Sale Agmt
Date of Agreement			Jan. 19, 2013
Cancellation of loans			$ 28,818
CEO
Loan from related party			5,000			$ 36,000
Repayment of loans to related parties			$ 41,000
Shareholder
Loan from related party					$ 6,000
Interest Rate					8.00%
Interest expense, related party					$ (217)
Employment Agmt
Date of Agreement			Sep. 6, 2013
Term of Agreement			2 years
Annual Compensation			$ 275,000
Options to purchase			3,000,240
Options to purchase, exercise price			$ 0.02
Bonus			$ 68,750
Earnings			137,500	$ 151,422
Accrued Earnings			$ 258,130		$ 154,062

Stock Deposits (Details Narrati

Stock Deposits (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015	Mar. 31, 2014
Notes to Financial Statements
Stock deposits reclassified as common stock and stock warrants		$ 147,050		$ 147,050
Shares Issued in Exchange for stock deposits			1,469,000

Convertible Note Payable (Detai

Convertible Note Payable (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended		12 Months Ended
	Oct. 31, 2015	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Debt Instrument, Converted Amount			$ 308,451	$ 12,000
Common Stock, shares issued					1,469,000
Convertible Prom Note #1
Date of Agreement					Mar. 11, 2014
Convertible Note					$ 37,500
Interest Rate					8.00%
Due Date					Dec. 13, 2014
Interest Accrued					$ 0
Convertible Note, Balance					0
Debt Instrument, Converted Amount					37,500
Debt Instrument, Interest Accrued, Converted Amount					$ 1,500
Common Stock, shares issued					2,159,271
Convertible Prom Note #2
Date of Agreement					Apr. 8, 2014
Convertible Note					$ 53,000
Interest Rate					8.00%
Due Date					Jan. 14, 2015
Interest Accrued					$ 0
Convertible Note, Balance					0
Debt Instrument, Converted Amount					53,000
Debt Instrument, Interest Accrued, Converted Amount					$ 2,120
Common Stock, shares issued					6,089,041
Convertible Prom Note #3
Date of Agreement					May 21, 2014
Convertible Note					$ 42,500
Interest Rate					8.00%
Due Date					Feb. 23, 2015
Interest Accrued					$ 0
Convertible Note, Balance					0
Debt Instrument, Converted Amount					42,500
Debt Instrument, Interest Accrued, Converted Amount					$ 1,700
Common Stock, shares issued					15,252,347
Convertible Prom Note #4
Date of Agreement					Aug. 14, 2014
Convertible Note					$ 66,780
Interest Rate					8.00%
Due Date					Aug. 14, 2015
Interest Accrued					$ 0
Convertible Note, Balance					0
Original Issue Discount					3,380
Debt Instrument, Converted Amount					66,780
Debt Instrument, Interest Accrued, Converted Amount					$ 2,850
Common Stock, shares issued					121,442,490
Convertible Prom Note #5
Date of Agreement					Aug. 14, 2014
Convertible Note					$ 58,300
Interest Rate					8.00%
Due Date					Aug. 14, 2015
Interest Accrued					$ 0
Convertible Note, Balance					0
Original Issue Discount					3,300
Debt Instrument, Converted Amount					58,300
Debt Instrument, Interest Accrued, Converted Amount					$ 2,527
Common Stock, shares issued					131,091,236
Convertible Prom Note #6
Date of Agreement					Aug. 13, 2014
Convertible Note					$ 61,111
Interest Rate					12.00%
Due Date					Aug. 14, 2016
Interest Accrued			1,067
Convertible Note, Balance					$ 0
Original Issue Discount					5,500
Debt Instrument, Converted Amount					61,111
Debt Instrument, Interest Accrued, Converted Amount					$ 6,266
Common Stock, shares issued					140,370,000
Convertible Prom Note #7
Date of Agreement					Aug. 19, 2014
Convertible Note					$ 57,895
Interest Rate					12.00%
Due Date					Aug. 19, 2016
Interest Accrued					$ 0
Convertible Note, Balance					0
Original Issue Discount					2,895
Debt Instrument, Converted Amount					57,895
Debt Instrument, Interest Accrued, Converted Amount					$ 14,035
Common Stock, shares issued					179,825,000
Convertible Prom Note #8
Date of Agreement					Sep. 18, 2014
Convertible Note					$ 64,500
Interest Rate					12.00%
Due Date					Sep. 18, 2015
Interest Accrued			0		$ 7,740
Convertible Note, Balance			0		54,500
Original Issue Discount					5,500
Original Issue Discount, unamortized					2,523
Debt Instrument, Converted Amount			54,500		$ 10,000
Debt Instrument, Interest Accrued, Converted Amount			$ 8,240
Common Stock, shares issued			187,959,744		18,181,818
Convertible Prom Note #9
Date of Agreement					Sep. 23, 2014
Convertible Note					$ 55,000
Interest Rate					8.00%
Due Date					Jun. 23, 2015
Interest Accrued			$ 0		$ 2,162
Convertible Note, Balance			0		29,800
Debt Instrument, Converted Amount			29,800		$ 25,200
Debt Instrument, Interest Accrued, Converted Amount			$ 2,158
Common Stock, shares issued			86,467,222		70,000,000
Convertible Prom Note #10
Date of Agreement					Oct. 6, 2014
Convertible Note					$ 33,000
Interest Rate					8.00%
Due Date					Jul. 6, 2015
Interest Accrued			$ 0		$ 1,273
Convertible Note, Balance			0
Debt Instrument, Converted Amount			33,000
Debt Instrument, Interest Accrued, Converted Amount			$ 1,320
Common Stock, shares issued			78,000,000
Convertible Prom Note #11
Date of Agreement					Nov. 6, 2014
Convertible Note					$ 55,000
Interest Rate					12.00%
Due Date					May 6, 2015
Interest Accrued			$ 0		$ 2,622
Convertible Note, Balance			0
Debt Instrument, Converted Amount			55,000
Debt Instrument, Interest Accrued, Converted Amount			$ 3,553
Common Stock, shares issued			281,363,421
Convertible Prom Note #12
Date of Agreement					Nov. 25, 2014
Convertible Note					$ 43,000
Interest Rate					8.00%
Due Date					Aug. 28, 2015
Interest Accrued			$ 2,064		$ 1,188
Convertible Note, Balance			530
Debt Instrument, Converted Amount	$ 2,250	$ 10,000	$ 45,980
Common Stock, shares issued	37,500,000	166,666,667	281,363,421
Convertible Prom Note #13
Date of Agreement					Dec. 16, 2014
Convertible Note					$ 33,333
Interest Rate					12.00%
Due Date					Dec. 16, 2016
Interest Accrued			$ 5,262		$ 4,000
Convertible Note, Balance			861
Original Issue Discount					3,333
Original Issue Discount, unamortized			2,021		$ 2,854
Debt Instrument, Converted Amount			$ 32,472
Common Stock, shares issued			423,700,000
Convertible Prom Note #14
Date of Agreement					Jan. 9, 2015
Convertible Note					$ 33,000
Interest Rate					8.00%
Due Date					Oct. 13, 2015
Interest Accrued			$ 1,909		$ 586
Debt Instrument, Converted Amount	$ 8,400
Common Stock, shares issued	140,000,000
Convertible Prom Note #15
Date of Agreement					Feb. 5, 2015
Convertible Note					$ 54,000
Interest Rate					8.00%
Due Date					Nov. 9, 2015
Interest Accrued			2,805		$ 639
Convertible Prom Note #16
Date of Agreement					Feb. 17, 2015
Convertible Note					$ 66,780
Interest Rate					8.00%
Due Date					Aug. 14, 2015
Interest Accrued			1,701		$ 615
Convertible Note, Balance			34,500
Original Issue Discount					6,780
Original Issue Discount, unamortized					$ 2,835
Debt Instrument, Converted Amount			32,280
Debt Instrument, Interest Accrued, Converted Amount			$ 755
Common Stock, shares issued			331,318,989
Convertible Prom Note #17
Date of Agreement					Feb. 25, 2015
Convertible Note					$ 27,778
Interest Rate					12.00%
Due Date					Feb. 25, 2017
Interest Accrued			$ 5,005		$ 3,333
Original Issue Discount, unamortized			1,954		$ 2,778
Convertible Prom Note #18
Date of Agreement					Mar. 9, 2015
Convertible Note					$ 55,000
Interest Rate					8.00%
Due Date					Dec. 9, 2015
Interest Accrued			187		$ 265
Convertible Note, Balance			49,292
Debt Instrument, Converted Amount		$ 7,974	5,708
Debt Instrument, Interest Accrued, Converted Amount			$ 2,266
Common Stock, shares issued		177,203,333	177,203,333
Convertible Prom Note #19
Date of Agreement					Mar. 26, 2015
Convertible Note					$ 29,680
Interest Rate					8.00%
Due Date					Mar. 23, 2016
Interest Accrued			$ 1,222		$ 32
Original Issue Discount					1,680
Original Issue Discount, unamortized			831		$ 1,653
Convertible Prom Note #20
Date of Agreement					Mar. 2, 2015
Convertible Note					$ 58,300
Interest Rate					8.00%
Due Date					Aug. 14, 2015
Interest Accrued			0		$ 12
Convertible Note, Balance			0		1,898
Original Issue Discount					3,300
Original Issue Discount, unamortized					107
Debt Instrument, Converted Amount			1,898		$ 56,402
Debt Instrument, Interest Accrued, Converted Amount			$ 20
Common Stock, shares issued			5,300,000		121,555,062
Convertible Prom Note #21
Date of Agreement			May 5, 2015
Convertible Note			$ 68,900
Interest Rate			8.00%
Due Date			May 5, 2016
Interest Accrued			$ 2,235
Original Issue Discount, unamortized			$ 2,275
Convertible Prom Note #22
Date of Agreement			May 6, 2015
Convertible Note			$ 10,500
Interest Rate			8.00%
Due Date			Feb. 8, 2016
Interest Accrued			$ 338
Convertible Prom Note #23
Date of Agreement			May 27, 2015
Convertible Note			$ 16,500
Interest Rate			8.00%
Due Date			May 28, 2016
Interest Accrued			$ 456
Original Issue Discount, unamortized			$ 979
Convertible Prom Note #24
Date of Agreement			Aug. 28, 2015
Convertible Note			$ 15,000
Interest Rate			8.00%
Due Date			Aug. 28, 2016
Interest Accrued			$ 108
Convertible Prom Note #25
Date of Agreement			Sep. 4, 2015
Convertible Note			$ 19,000
Interest Rate			8.00%
Due Date			Jun. 4, 2016
Interest Accrued			$ 108

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Notes to Financial Statements
Change in value of derivative liability	$ (180,446)	$ 8,735	$ (230,186)	$ 8,735
Derivative expense	(142,073)	$ (109,872)	335,244	$ 109,872
Debt Discount, Unamortized	173,873		173,873
Derivative liabilities	405,496		405,496		$ 139,983
Derivative liabilities	$ 33,370		$ 33,370		$ 77,775

Equity Transactions - Schedule

Equity Transactions - Schedule of Value of Warrants (Details) - USD ($)	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Fair value allocation of proceeds	$ 13,259
Warrant #1
Date	Oct. 29, 2013
Warrants	$ 250,000
Stock price on grant date	$ 0.30
Exercise price	$ 0.50
Expected life	1 year
Volatility	147.00%
Risk-free rate	0.12%
Calculated value	$ 10,473
Fair value allocation of proceeds	$ 7,381
Warrant #2
Date	Dec. 11, 2013
Warrants	$ 250,000
Stock price on grant date	$ 0.30
Exercise price	$ 0.50
Expected life	1 year
Volatility	64.00%
Risk-free rate	0.11%
Calculated value	$ 0
Fair value allocation of proceeds	$ 0
Warrant #3
Date	Mar. 10, 2014
Warrants	$ 83,334
Stock price on grant date	$ 0.30
Exercise price	$ 0.50
Expected life	1 year
Volatility	65.00%
Risk-free rate	0.13%
Calculated value	$ 0
Fair value allocation of proceeds	$ 0
Warrant #4
Date	Apr. 4, 2014
Warrants	$ 83,334
Stock price on grant date	$ 0.30
Exercise price	$ 0.50
Expected life	1 year
Volatility	113.00%
Risk-free rate	0.12%
Calculated value	$ 3,181
Fair value allocation of proceeds	$ 2,822
Warrant #5
Date	Apr. 24, 2014
Warrants	$ 1,000,000
Stock price on grant date	$ 0.25
Exercise price	$ 0.35
Expected life	3 years
Volatility	76.00%
Risk-free rate	0.84%
Calculated value	$ 104,416
Fair value allocation of proceeds	$ 73,653
Warrant #6
Date	Jul. 10, 2014
Warrants	$ 700,000
Stock price on grant date	$ 0.037
Exercise price	$ 0.15
Expected life	3 years
Volatility	119.00%
Risk-free rate	0.96%
Calculated value	$ 12,130
Fair value allocation of proceeds	$ 8,627
Warrant #7
Date	Jul. 29, 2014
Warrants	$ 700,000
Stock price on grant date	$ 0.037
Exercise price	$ 0.15
Expected life	3 years
Volatility	119.00%
Risk-free rate	0.98%
Calculated value	$ 12,102
Fair value allocation of proceeds	$ 8,992
Warrant #8
Date	Jun. 9, 2015
Warrants	$ 90,000,000
Stock price on grant date	$ 0.0002
Exercise price	$ 0.0002
Expected life	5 years
Volatility	98.00%
Risk-free rate	1.74%
Calculated value	$ 13,259
Fair value allocation of proceeds	$ 13,259

Equity Transactions - Schedul34

Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Sep. 30, 2015	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, Issued Warrants	3,066,668	583,334	583,334
Beginning Balance, Average Exercise Price	$ 0.29	$ 0.50	$ .50
Issued, Warrants	90,000,000	2,483,334
Issued, Average Exercise Price	$ 0.0002	$ 0.24
Exercised, Warrants
Exercised, Average Exercise Price
Expired Warrants
Expired Average Exercise Price
Ending Balance, Issued Warrants	93,066,668	3,066,668	583,334
Ending Balance, Average Exercise Price	$ 0.0097	$ 0.29	$ 0.50

Equity Transactions - Schedul35

Equity Transactions - Schedule of Value of Options (Details)	6 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Stock Option 1
Date of Issuance	Sep. 6, 2013
Options | shares	41,003,280
Stock price on grant date	$ 0.02
Exercise price	0.0191984
Exercise Price, Modified	$ 0.0008
Expected life	10 years
Volatility	76.00%
Risk-free rate	2.94%
Calculated value | $	$ 663,307
Calcuated Value, Modified | $	$ 694,250
Stock Option 2
Date of Issuance	Feb. 7, 2014
Options | shares	1,500,000
Stock price on grant date	$ 0.02
Exercise price	0.0191984
Exercise Price, Modified	$ 0.0008
Expected life	10 years
Volatility	74.00%
Risk-free rate	2.71%
Calculated value | $	$ 23,825
Calcuated Value, Modified | $	$ 24,920
Stock Option 3
Date of Issuance	Mar. 14, 2014
Options | shares	5,000,000
Stock price on grant date	$ 0.30
Exercise price	0.30
Exercise Price, Modified	$ 0.0008
Expected life	10 years
Volatility	74.00%
Risk-free rate	2.65%
Calculated value | $	$ 1,182,141
Calcuated Value, Modified | $	$ 1,189,569
Stock Option 4
Date of Issuance	May 7, 2014
Options | shares	3,500,000
Stock price on grant date	$ .12
Exercise price	.12
Exercise Price, Modified	$ 0.0008
Expected life	10 years
Volatility	73.00%
Risk-free rate	2.56%
Calculated value | $	$ 315,772
Calcuated Value, Modified | $	$ 320,159
Stock Option 5
Date of Issuance	Jul. 23, 2014
Options | shares	750,000
Stock price on grant date	$ .069
Exercise price	.069
Exercise Price, Modified	$ 0.0008
Expected life	10 years
Volatility	88.00%
Risk-free rate	2.53%
Calculated value | $	$ 45,109
Calcuated Value, Modified | $	$ 45,927
Stock Option 6
Date of Issuance	Oct. 6, 2014
Options | shares	15,500,000
Stock price on grant date	$ .0358
Exercise price	.0191984
Exercise Price, Modified	$ 0.0008
Expected life	5 years
Volatility	101.00%
Risk-free rate	1.04%
Calculated value | $	$ 454,798
Calcuated Value, Modified | $	$ 469,891
Stock Option 7
Date of Issuance	Apr. 6, 2015
Options | shares	204,000,250
Stock price on grant date	$ 0.0008
Exercise price	0.0008
Exercise Price, Modified	$ 0.0008
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.31%
Calculated value | $	$ 120,788
Calcuated Value, Modified | $	$ 120,778
Stock Option 8
Date of Issuance	Jun. 9, 2015
Options | shares	100,000,000
Stock price on grant date	$ 0.0002
Exercise price	0.0002
Exercise Price, Modified	$ 0.0001
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.74%
Calculated value | $	$ 14,838
Calcuated Value, Modified | $	$ 16,347

Equity Transactions - Schedul36

Equity Transactions - Schedule of Option Activity (Details) - shares	6 Months Ended	12 Months Ended
	Sep. 30, 2015	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, number of shares	67,253,280	47,503,280	47,503,280
Beginning Balance, weighted average exercise price	0.0001	0.0001	0.0001
Options granted, number of shares	304,000,250	19,750,000
Options granted, weighted average exercise price	0.0001	0.0001
Options exercised, number of shares
Options exercised, weighted average exercise price
Options expired, number of shares
Options expired, weighted average exercise price
Ending Balance, number of shares	371,253,530	67,253,280	47,503,280
Ending Balance, weighted average exercise price	0.0001	0.0001	0.0001

Equity Transactions (Details Na

Equity Transactions (Details Narrative)	6 Months Ended		12 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Mar. 31, 2015$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares	Jul. 18, 2013shares
Common Stock, Shares Authorized	37,503,000,000		37,503,000,000	37,503,000,000	90,000,000
Common Stock, Par Value | $ / shares	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000		10,000,000
Preferred Stock, Par Value | $ / shares	$ 0.001		$ 0.001
Series A Preferred Stock, Designated						6,000,000
Common Stock, Issued	4,072,077,779		1,541,083,957
Preferred Stock, Issued	6,000,000		6,000,000
Common Stock, shares issued			1,469,000
Stock split ratio	416.7
Options granted, number of shares	304,000,250		19,750,000
Shares issued for services, value | $	$ 796,050
Debt Instrument, Converted Amount | $	$ 308,451	$ 12,000
Legal Services
Shares issued for services	1,000,000
Shares issued for services, value | $	$ 30,000
Date	Jul. 1, 2014
Warrant #6
Common Stock, shares issued	700,000
Date	Jul. 10, 2014
Warrants | $	$ 700,000
Stock price on grant date | $ / shares	$ 0.043
Exercise price | $ / shares	$ 0.15
Expected life	3 years
Warrant #7
Common Stock, shares issued	700,000
Date	Jul. 29, 2014
Warrants | $	$ 700,000
Stock price on grant date | $ / shares	$ 0.05
Exercise price | $ / shares	$ 0.15
Expected life	3 years
Debt Conversion #1
Date of Agreement	Sep. 22, 2014
Common Stock, shares issued	550,459
Common Stock, price per share | $ / shares	$ 0.0218
Debt Instrument, Converted Amount | $	$ 12,000
Debt Conversion #2
Date of Agreement	Oct. 1, 2014
Common Stock, shares issued	648,649
Common Stock, price per share | $ / shares	$ 0.0185
Debt Instrument, Converted Amount | $	$ 12,000
Debt Conversion #3
Date of Agreement	Oct. 8, 2014
Common Stock, shares issued	505,618
Common Stock, price per share | $ / shares	$ 0.0178
Debt Instrument, Converted Amount | $	$ 9,000
Debt Conversion #4
Date of Agreement	Oct. 16, 2014
Common Stock, shares issued	454,545
Common Stock, price per share | $ / shares	$ 0.0132
Debt Instrument, Converted Amount | $	$ 6,000
Debt Conversion #5
Date of Agreement	Oct. 29, 2014
Common Stock, shares issued	1,250,000
Common Stock, price per share | $ / shares	$ 0.0120
Debt Instrument, Converted Amount | $	$ 15,000
Debt Conversion #6
Date of Agreement	Nov. 3, 2014
Common Stock, shares issued	819,672
Common Stock, price per share | $ / shares	$ 0.0122
Debt Instrument, Converted Amount | $	$ 10,000
Debt Conversion #7
Date of Agreement	Nov. 7, 2014
Common Stock, shares issued	1,188,119
Common Stock, price per share | $ / shares	$ 0.0101
Debt Instrument, Converted Amount | $	$ 12,000
Debt Conversion #8
Date of Agreement	Nov. 19, 2014
Common Stock, shares issued	2,831,250
Common Stock, price per share | $ / shares	$ 0.0064
Debt Instrument, Converted Amount | $	$ 18,120
Debt Conversion #9
Date of Agreement	Dec. 8, 2014
Common Stock, shares issued	3,488,372
Common Stock, price per share | $ / shares	$ 0.0043
Debt Instrument, Converted Amount | $	$ 15,000
Debt Conversion #10
Date of Agreement	Dec. 15, 2014
Common Stock, shares issued	4,285,714
Common Stock, price per share | $ / shares	$ 0.0028
Debt Instrument, Converted Amount | $	$ 12,000
Debt Conversion #11
Date of Agreement	Dec. 26, 2014
Common Stock, shares issued	7,478,261
Common Stock, price per share | $ / shares	$ 0.0023
Debt Instrument, Converted Amount | $	$ 17,200
Debt Conversion #12
Date of Agreement	Feb. 11, 2015
Common Stock, shares issued	74,750,000
Common Stock, price per share | $ / shares	$ 0.0004
Debt Instrument, Converted Amount | $	$ 29,900
Debt Conversion #13
Date of Agreement	Feb. 12, 2015
Common Stock, shares issued	37,356,055
Common Stock, price per share | $ / shares	$ 0.00046
Debt Instrument, Converted Amount | $	$ 17,333
Debt Conversion #14
Date of Agreement	Feb. 15, 2015
Common Stock, shares issued	73,924,324
Common Stock, price per share | $ / shares	$ 0.00048
Debt Instrument, Converted Amount | $	$ 35,730
Debt Conversion #26
Date of Agreement	Apr. 1, 2015
Common Stock, shares issued	41,111,111
Common Stock, price per share | $ / shares	$ 0.00041
Debt Instrument, Converted Amount | $	$ 16,650
Debt Conversion #27
Date of Agreement	Apr. 6, 2015
Common Stock, shares issued	20,964,361
Common Stock, price per share | $ / shares	$ 0.00048
Debt Instrument, Converted Amount | $	$ 10,000
Debt Conversion #28
Date of Agreement	Apr. 8, 2015
Common Stock, shares issued	45,356,111
Common Stock, price per share | $ / shares	$ 0.00034
Debt Instrument, Converted Amount | $	$ 15,309
Debt Conversion #29
Date of Agreement	Apr. 9, 2015
Common Stock, shares issued	32,545,455
Common Stock, price per share | $ / shares	$ 0.00044
Debt Instrument, Converted Amount | $	$ 14,320
Debt Conversion #30
Date of Agreement	Apr. 14, 2015
Common Stock, shares issued	23,696,682
Common Stock, price per share | $ / shares	$ 0.00042
Debt Instrument, Converted Amount | $	$ 10,000
Debt Conversion #31
Date of Agreement	Apr. 16, 2015
Common Stock, shares issued	5,300,000
Common Stock, price per share | $ / shares	$ 0.00036
Debt Instrument, Converted Amount | $	$ 1,918
Debt Conversion #32
Date of Agreement	Apr. 21, 2015
Common Stock, shares issued	25,974,026
Common Stock, price per share | $ / shares	$ 0.00036
Debt Instrument, Converted Amount | $	$ 10,000
Debt Conversion #33
Date of Agreement	Apr. 29, 2015
Common Stock, shares issued	38,961,039
Common Stock, price per share | $ / shares	$ 0.00039
Debt Instrument, Converted Amount | $	$ 15,000
Debt Conversion #34
Date of Agreement	May 4, 2015
Common Stock, shares issued	13,146,439
Common Stock, price per share | $ / shares	$ 0.00039
Debt Instrument, Converted Amount | $	$ 5,083
Debt Conversion #35
Date of Agreement	May 12, 2015
Common Stock, shares issued	90,337,960
Common Stock, price per share | $ / shares	$ 0.00031
Debt Instrument, Converted Amount | $	$ 28,456
Debt Conversion #36
Date of Agreement	May 20, 2015
Common Stock, shares issued	94,764,514
Common Stock, price per share | $ / shares	$ 0.00021
Debt Instrument, Converted Amount | $	$ 20,199
Debt Conversion #37
Date of Agreement	May 20, 2015
Common Stock, shares issued	78,363,636
Common Stock, price per share | $ / shares	$ 0.00022
Debt Instrument, Converted Amount | $	$ 17,240
Debt Conversion #38
Date of Agreement	May 27, 2015
Common Stock, shares issued	70,180,137
Common Stock, price per share | $ / shares	$ 0.00019
Debt Instrument, Converted Amount | $	$ 13,568
Debt Conversion #39
Date of Agreement	May 29, 2015
Common Stock, shares issued	88,235,295
Common Stock, price per share | $ / shares	$ 0.00017
Debt Instrument, Converted Amount | $	$ 15,000
Debt Conversion #40
Date of Agreement	Jun. 11, 2015
Common Stock, shares issued	94,260,947
Common Stock, price per share | $ / shares	$ 0.00010
Debt Instrument, Converted Amount | $	$ 9,897
Debt Conversion #41
Date of Agreement	Jun. 16, 2015
Common Stock, shares issued	117,500,000
Common Stock, price per share | $ / shares	$ 0.00012
Debt Instrument, Converted Amount | $	$ 14,100
Debt Conversion #42
Date of Agreement	Jun. 16, 2015
Common Stock, shares issued	113,041,667
Common Stock, price per share | $ / shares	$ 0.00012
Debt Instrument, Converted Amount | $	$ 13,565
Debt Conversion #43
Date of Agreement	Apr. 8, 2015
Common Stock, shares issued	45,454,545
Common Stock, price per share | $ / shares	$ 0.00044
Debt Instrument, Converted Amount | $	$ 20,000
Debt Conversion #44
Date of Agreement	Jun. 22, 2015
Common Stock, shares issued	123,583,333
Common Stock, price per share | $ / shares	$ 0.00006
Debt Instrument, Converted Amount | $	$ 7,415
Debt Conversion #45
Date of Agreement	Jun. 22, 2015
Common Stock, shares issued	247,992,413
Common Stock, price per share | $ / shares	$ 0.00006
Debt Instrument, Converted Amount | $	$ 14,384
Grant of Stock
Common Stock, shares issued	90,000,000
Date	Jun. 9, 2014
Warrants | $	$ 90,000,000
Stock price on grant date | $ / shares	$ 0.0002
Exercise price | $ / shares	$ 0.0002
Expected life	5 years
Sale of Stock #1
Common Stock, shares issued	10,037,107
Common Stock, price per share | $ / shares	$ 0.000498
Sale of Stock #2
Common Stock, shares issued	154,245,477
Common Stock, price per share | $ / shares	$ 0.00007
Sale of Stock #3
Common Stock, shares issued	161,942,326
Common Stock, price per share | $ / shares	$ 0.00007
Sale of Stock #4
Common Stock, shares issued	143,928,240
Common Stock, price per share | $ / shares	$ 0.00007
2013 Stock Option Plan Amendment
Exercise price | $ / shares	$ 0.0008
Debt Conversion #46
Date of Agreement	Jun. 23, 2015
Common Stock, shares issued	129,200,000
Common Stock, price per share | $ / shares	$ 0.00006
Debt Instrument, Converted Amount | $	$ 7,752
Debt Conversion #47
Date of Agreement	Sep. 16, 2015
Common Stock, shares issued	177,203,333
Common Stock, price per share | $ / shares	$ 0.000045
Debt Instrument, Converted Amount | $	$ 7,974
Debt Conversion #48
Date of Agreement	Sep. 28, 2015
Common Stock, shares issued	166,666,667
Common Stock, price per share | $ / shares	$ 0.00006
Debt Instrument, Converted Amount | $	$ 10,000
Debt Conversion #49
Date of Agreement	Sep. 29, 2015
Common Stock, shares issued	177,000,000
Common Stock, price per share | $ / shares	$ 0.00006
Debt Instrument, Converted Amount | $	$ 10,620
Asset Assign Agmt #2
Date of Agreement	Oct. 6, 2014
Common Stock, shares issued	220,792,028
Shares Issued, Value | $	$ 7,904,355
Asset Assign Agmt
Date of Agreement	Jul. 18, 2015
Common Stock, shares issued	82,767,038
Series A Preferred Stock, shares issued	6,000,000
Shares Issued, Value | $	$ 123,973
Sale Agmt
Shares agreed to cancel	262,521,000
Shares returned to treasury	500,255,434
Date of Agreement	Jul. 19, 2013
Consultant
Shares issued for services	2,500,000
Shares issued for services, value | $	$ 300,000
Date	May 7, 2014
Stock Deposits
Common Stock, shares issued	1,469,000
Shares Issued, Value | $	$ 147,050
Date	Jun. 16, 2014
Warrant #1
Common Stock, shares issued	250,000
Date	Oct. 29, 2013
Warrants | $	$ 250,000
Stock price on grant date | $ / shares	$ 0.30
Exercise price | $ / shares	$ 0.50
Expected life	1 year
Warrant #2
Common Stock, shares issued	250,000
Date	Dec. 11, 2013
Warrants | $	$ 250,000
Stock price on grant date | $ / shares	$ 0.30
Exercise price | $ / shares	$ 0.50
Expected life	1 year
Warrant #3
Common Stock, shares issued	83,334
Date	Mar. 10, 2014
Warrants | $	$ 83,334
Stock price on grant date | $ / shares	$ 0.30
Exercise price | $ / shares	$ 0.50
Expected life	1 year
Warrant #4
Common Stock, shares issued	83,334
Date	Apr. 4, 2014
Warrants | $	$ 83,334
Stock price on grant date | $ / shares	$ 0.30
Exercise price | $ / shares	$ 0.50
Expected life	1 year
Warrant #5
Common Stock, shares issued	1,000,000
Date	Apr. 24, 2014
Warrants | $	$ 1,000,000
Stock price on grant date | $ / shares	$ 0.25
Exercise price | $ / shares	$ 0.35
Expected life	3 years
CEO
Date of Agreement	Oct. 6, 2014
Shares issued for services	8,000,000
Attorney
Date of Agreement	Oct. 6, 2014
Shares issued for services	4,000,000
Vendor
Shares issued for services	500,000
Shares issued for services, value | $	$ 6,450
Investment Agmt
Date of Agreement	Aug. 13, 2014
Shares issued for services	79,961,892
Shares issued for services, value | $	$ 220,000
Debt Conversion #15
Date of Agreement	Feb. 13, 2015
Common Stock, shares issued	37,280,000
Common Stock, price per share | $ / shares	$ 0.00048
Debt Instrument, Converted Amount | $	$ 17,894
Debt Conversion #16
Date of Agreement	Feb. 17, 2015
Common Stock, shares issued	36,643,945
Common Stock, price per share | $ / shares	$ 0.00046
Debt Instrument, Converted Amount | $	$ 17,003
Debt Conversion #17
Date of Agreement	Feb. 23, 2015
Common Stock, shares issued	47,090,000
Common Stock, price per share | $ / shares	$ 0.00044
Debt Instrument, Converted Amount | $	$ 20,603
Debt Conversion #18
Date of Agreement	Feb. 23, 2015
Common Stock, shares issued	36,643,945
Common Stock, price per share | $ / shares	$ 0.00046
Debt Instrument, Converted Amount | $	$ 17,003
Debt Conversion #19
Date of Agreement	Feb. 24, 2015
Common Stock, shares issued	20,447,291
Common Stock, price per share | $ / shares	$ 0.00046
Debt Instrument, Converted Amount | $	$ 9,488
Debt Conversion #20
Date of Agreement	Feb. 26, 2015
Common Stock, shares issued	105,075,000
Common Stock, price per share | $ / shares	$ 0.0004
Debt Instrument, Converted Amount | $	$ 42,030
Debt Conversion #21
Date of Agreement	Feb. 27, 2015
Common Stock, shares issued	56,000,000
Common Stock, price per share | $ / shares	$ 0.00048
Debt Instrument, Converted Amount | $	$ 26,880
Debt Conversion #22
Date of Agreement	Mar. 2, 2015
Common Stock, shares issued	121,555,062
Common Stock, price per share | $ / shares	$ 0.00046
Debt Instrument, Converted Amount | $	$ 56,402
Debt Conversion #23
Date of Agreement	Mar. 9, 2015
Common Stock, shares issued	47,518,166
Common Stock, price per share | $ / shares	$ 0.00071
Debt Instrument, Converted Amount | $	$ 33,900
Debt Conversion #24
Date of Agreement	Mar. 10, 2015
Common Stock, shares issued	70,000,000
Common Stock, price per share | $ / shares	$ 0.00036
Debt Instrument, Converted Amount | $	$ 25,200
Debt Conversion #25
Date of Agreement	Mar. 20, 2015
Common Stock, shares issued	18,181,818
Common Stock, price per share | $ / shares	$ 0.00006
Debt Instrument, Converted Amount | $	$ 10,000
Warrant #8
Date	Jun. 9, 2015
Warrants | $	$ 90,000,000
Stock price on grant date | $ / shares	$ 0.0002
Exercise price | $ / shares	$ 0.0002
Expected life	5 years

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Mar. 31, 2015USD ($)
Accounting Policies [Abstract]
Monthly Rent	$ 2,600

Income Taxes - Schedule of Fede

Income Taxes - Schedule of Federal Income Tax (Details) - USD ($)	6 Months Ended	12 Months Ended
	Sep. 30, 2015	Mar. 31, 2015
Federal income tax benefit attributable to:
Current operations	$ 325,369	$ 1,405,416
Less: valuation allowance	(325,369)	(1,405,416)
Net provision for Federal income taxes	$ 0	$ 0

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Asset (Details) - USD ($)	Sep. 30, 2015	Mar. 31, 2015
Deferred tax asset attributable to:
Net operating loss carryover	$ 2,780,320	$ 2,454,951
Less: valuation allowance	(2,780,320)	(2,454,951)
Net deferred tax asset	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Mar. 31, 2015USD ($)
Income Tax Disclosure [Abstract]
Net Operating Loss Carry-Forwards	$ 8,391,947
Operating Loss Carry-Forwards Expiration Date	Jan. 1, 2033
Effective Tax Rate	34.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended		12 Months Ended
	Oct. 31, 2015	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Common Stock, shares issued					1,469,000
Issued, Warrants			90,000,000		2,483,334
Debt Instrument, Converted Amount			$ 308,451	$ 12,000
Convertible Prom Note #18
Date of Issuance		Sep. 29, 2015
Common Stock, shares issued		177,203,333	177,203,333
Date of Agreement					Mar. 9, 2015
Convertible Note					$ 55,000
Interest Rate					8.00%
Due date					Dec. 9, 2015
Debt Instrument, Converted Amount		$ 7,974	$ 5,708
Debt Instrument, Remaining Principal Balance			$ 49,292
Convertible Prom Note #14
Common Stock, shares issued	140,000,000
Date of Agreement					Jan. 9, 2015
Convertible Note					$ 33,000
Interest Rate					8.00%
Due date					Oct. 13, 2015
Debt Instrument, Converted Amount	$ 8,400
Convertible Prom Note #12
Common Stock, shares issued	37,500,000	166,666,667	281,363,421
Date of Agreement					Nov. 25, 2014
Convertible Note					$ 43,000
Interest Rate					8.00%
Due date					Aug. 28, 2015
Debt Instrument, Converted Amount	$ 2,250	$ 10,000	$ 45,980
Debt Instrument, Remaining Principal Balance			$ 530